In order to address the latter possibility, and to explore how timing of treatment during postnatal skeletal development affects efficacy, we generated a new mouse model of MPS VI where function of Arsb can be restored at desired time points. This evidence concerns the gene ARSB and mucopolysaccharidosis type 6.